Misoclear

Misoprostol

Method of action: Antiulcer, Drugs For Acid Related Disorders, Prostaglandin-Like, Stimulating Generic Activity

Treatment option: Duodenal Ulcer, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Misoclear

Property	Description
Active Ingredient	Misoprostol
Form	Tablet (Solid Dosage Form)
Pharmacological Class	Synthetic Prostaglandin E₁ Analogue
General Purpose	Gastric cytoprotection and Uterine contraction
Origin	Synthetic

What Type of Medicine is Misoclear (Misoprostol)?

Misoclear is a medicinal preparation whose sole active ingredient is Misoprostol, a chemically manufactured compound classified as a Synthetic Prostaglandin E₁ Analogue. This classification means the compound is designed to precisely mimic the regulatory actions of the body's natural prostaglandin E₁. Misoprostol falls into two primary high-level pharmacological classes: it is both an Antisecretory agent and a potent Uterotonic agent. This dual physiological capacity is widely clinically recognized for its utility in distinct medical fields, confirming its versatility.

Composition and Form: The Misoprostol Tablet

Misoclear is supplied as a Tablet, which is a solid dosage form containing the single active compound, Misoprostol. This product is classified as a single-agent product, relying exclusively on the effects of Misoprostol, unlike some combination products. The active compound is utilized for its gastrointestinal and uterotonic properties. The specific tablet formulation of Misoclear is manufactured to be suitable for various routes of administration, including oral, vaginal, or sublingual, which is a differentiating factor that allows medical professionals to select the appropriate route of administration based on the intended therapeutic goal.

General Purpose: Why is This Prostaglandin Analogue Used?

The general purpose of this medication is derived from its unique ability to modulate prostaglandin pathways, resulting in gastric cytoprotection and the stimulation of uterine contraction. A typical application is the prevention of severe gastrointestinal damage, specifically NSAID-induced ulcers, in patients deemed to be at high risk. Separate from its digestive role, its influence on uterine smooth muscle makes it essential for specialized medical interventions related to the reproductive system. These two core physiological actions define its primary identity and broad medical necessity.

What side effects are possible with Misoclear?

Possible Side Effects and Safety Information

The safety profile of Misoclear (Misoprostol) involves both common, expected reactions and rare, serious safety warnings, particularly regarding use during pregnancy.

Common and Expected Adverse Reactions

The most frequently reported side effects are primarily gastrointestinal and reproductive in nature. These effects are often temporary and may resolve within a few days to a week. They are more common early in treatment and may include:

Gastrointestinal: Diarrhea, abdominal pain, nausea, vomiting, and dyspepsia.
Reproductive/Uterine: Uterine contractions or cramping, heavy menstrual bleeding, and spotting.

Diarrhea is a very common, dose-related effect, which typically resolves on its own, but may require discontinuation of the drug in a small percentage of patients.

Serious Adverse Reactions and Safety Warnings

Serious risks are rare but require immediate attention. These include the potential for:

Severe Hemorrhage: Excessive vaginal bleeding, which may, in rare cases, necessitate blood transfusion or surgical intervention.
Uterine Rupture: This risk is elevated when the drug is used in a pregnant uterus, especially in patients with a prior Cesarean section or other major uterine surgery.
Serious Infection/Sepsis: Rare cases of severe bacterial infection, including fatal septic shock, have been reported following use.
Allergic Reactions: Rare but serious hypersensitivity reactions, such as anaphylaxis, hives, and swelling.

Population-Specific Safety Considerations

The use of Misoclear in women who are pregnant is a major safety concern. Administration during pregnancy, when used for non-obstetrical indications, is formally contraindicated due to the high risk of abortion, premature birth, and severe birth defects (teratogenic risk). Women of childbearing potential taking the drug for ulcer prevention must use effective contraception and have a negative pregnancy test prior to starting therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Misoclear (Misoprostol) is documented in regulatory labeling by a distinct profile of clinical manifestations and required emergency actions. The officially documented signs of excessive exposure involve several physiological systems.

Documented Clinical Manifestations

Specific central nervous system effects listed in regulatory documents include sedation, tremor, and convulsions. Gastrointestinal manifestations such as diarrhea and abdominal pain are also officially noted. The potential for more serious outcomes relates to the cardiovascular system, which may exhibit hypotension (low blood pressure) and bradycardia (slow heart rate), alongside palpitations and respiratory signs like dyspnea (shortness of breath). These manifestations define the regulatory basis for assessing the severity of the overdose.

Mandated Emergency Action

Regulatory information strictly mandates specific actions when overdose is suspected. Individuals must seek immediate medical attention and contact emergency services immediately due to the potential for severe or life-threatening symptoms. Treatment is officially defined as symptomatic and supportive because no specific antidote is known for this medication. Procedures described in regulatory context include the option of administering oral activated charcoal to help reduce absorption and the removal of any remaining undissolved tablets. It is also officially noted that hemodialysis is not expected to be useful for managing overdose.

Therapeutic Uses of Misoclear

The use of this medicine is applied across therapeutic domains involving symptomatic management and supportive care, relevant for easing certain gastrointestinal and reproductive health needs.

Managing the Risk of Stomach Ulcers

Misoprostol is commonly used across domains where additional symptomatic support is needed to help manage the risk of gastric ulcers in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). This is considered relevant in contexts involving heightened systemic burden, as it contributes to easing the overall symptom load related to inflammatory or irritative states. It is used for managing conditions that involve the risk of gastric ulcers during chronic NSAID therapy.

Supportive Management for Reproductive Situations

Applied in clinical settings that involve acute or unstable symptom patterns, misoprostol is relevant for easing symptoms associated with certain early pregnancies (medical abortion) or for supportive management of an incomplete abortion or miscarriage. In these scenarios, it helps address symptom clusters that create noticeable physiological strain, offering symptomatic relief that supports the patient during difficult episodes. It is also applied across domains where short-term symptomatic assistance is needed for the supportive management of heavy bleeding after childbirth (postpartum hemorrhage).

"This medicine provides support that helps ease the overall symptom burden and assists with maintaining functional stability."

Quick Fact: Supportive Management for Physiological Strain This medicine may assist with providing supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort.

Regulatory References

NIH MedlinePlus overview on Misoprostol

Eligibility and Restrictions for Use

The final eligibility profile for Misoclear (Misoprostol) is strictly determined by governmental regulatory documentation, defining populations that are contraindicated, restricted, or eligible.

Absolute Contraindications

The medicine is contraindicated and must not be used in pregnant women for the indication of preventing NSAID-induced ulcers. This is due to its potent abortifacient properties and the high risk of fetal harm. Use is also prohibited in individuals with a known hypersensitivity or allergy to Misoprostol, other prostaglandins, or any components of the tablet formulation.

Conditional Use and Restrictions

Eligibility is restricted for women of childbearing potential who must be at high risk of ulcer complications, must have a negative pregnancy test prior to starting therapy, and must use effective contraception throughout treatment. Patients with existing conditions such as severe renal impairment, hepatic impairment, or cardiovascular disease require the drug to be used with caution and close medical monitoring.

Age-Group and Developmental Status

The safety and effectiveness of Misoclear have not been established in the pediatric population (under 18 years of age) for the ulcer prevention indication. Older adults (geriatric patients) are generally eligible for use, and routine dosage adjustment is not typically required based on regulatory reviews. The drug’s active metabolites are excreted into human milk, requiring a decision between discontinuing nursing or discontinuing the medicine during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific co-administration restrictions for Misoclear (Misoprostol), primarily driven by pharmacodynamic and exposure-altering effects. The risk classifications are based on the documented outcomes of co-administration with other substances.

Classification	Official Regulatory Constraint
Pharmacodynamic Augmentation	Co-administration with other Oxytocic Agents (e.g., Oxytocin) is restricted or not recommended, as Misoprostol may augment their activity through pharmacodynamic synergism. Timing separation of at least 4 hours between the last Misoprostol dose and Oxytocin initiation is generally required.
Potentiation of GI Effects	Magnesium-containing Antacids must be avoided due to the documented risk of potentiating Misoprostol-induced diarrhea. Regulatory guidance recommends using aluminum- or calcium-containing antacids if an antacid is required.
Exposure Modification by Food/Antacids	The bioavailability of Misoprostol acid is reduced when the dose is taken with food or concomitant antacids, which can lower the C max (maximum plasma concentration).
Lack of Significant Interaction	Regulatory studies confirmed no clinically significant pharmacokinetic interaction with several common drugs, including Ibuprofen, Diclofenac, Propranolol, and Diazepam. A minor (20%) decrease in the AUC of Aspirin was officially stated as not clinically significant.
Population-Specific Exposure	Official data documents that exposure to Misoprostol acid (AUC and C max) is increased in both elderly patients and those with renal impairment.

The interaction profile is structured by mandatory constraints on substances that directly affect uterine activity or intensify gastrointestinal effects, while also providing confirmation of selective pharmacokinetic neutrality with several common co-administered medicines.

Mechanism of Action

Misoclear is a synthetic Prostaglandin E1 analog that functions as an agonist primarily at the Prostaglandin E receptor subtype EP3. This activation initiates two key mechanistic cascades in peripheral tissues. In the uterus, EP3 agonism on myometrial cells triggers G-protein coupled signaling, which increases intracellular calcium ion ( Ca^2+) levels. The resulting Ca^2+ surge initiates actin-myosin cross-bridge cycling, leading to frequent, pronounced, and prolonged uterine smooth muscle contraction and a reduction in cervical tone. Concurrently, in the gastrointestinal system, EP3 activation on gastric parietal cells inhibits adenylate cyclase, causing a decrease in cyclic AMP ( cAMP). This cAMP reduction suppresses the H^+/ K^+-ATPase (proton pump), resulting in gastric hyposecretion (reduced acid output) and enhanced mucosal defense factors. The co-occurrence of these mechanistic effects characterizes the drug's activity pattern.

Dosage and Administration Information

How to Use Misoclear: Official Administration Guidelines

Misoclear, containing Misoprostol, is used following highly specific administration protocols. The method of use, including route, dose, and frequency, differs substantially depending on the treatment goal.

Administration Route and Dosing

The approved administration route is primarily oral for gastric cytoprotection, but the tablet formulation also supports buccal administration for certain uterotonic regimens.

Indication Context	Standard Dosing Regimen	Frequency and Timing
NSAID-Induced Ulcer Prophylaxis	200 micrograms (mcg) per dose; 100 mcg if 200 mcg is poorly tolerated.	Four times daily (q.i.d.) with food, ensuring the last dose is taken at bedtime.
Uterotonic Use (in Combination)	800 mcg in a single application.	Administered 24 to 48 hours after the preceding medication in the regimen.

Administration Conditions and Constraints

For the oral regimen, Misoclear must be taken with food to manage practical tolerability, with a mandatory dose at bedtime. Additionally, official labeling advises against taking the medication concurrently with magnesium-containing antacids due to the potential for practical gastrointestinal effects.

Special Procedural Requirements

For the 800 mcg buccal regimen, the tablets must be placed in the cheek pouch and retained there for 30 minutes to allow for absorption, followed by swallowing any residual fragments with liquid. Regarding population adjustments, while no routine dose reduction is mandated for renal impairment, the dose may be reduced to 100 mcg per dose if the patient is unable to tolerate the standard 200 mcg dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence in Condition A

Research has explored whether this investigational agent has a potential effect on the symptoms of Condition A (e.g., gastric ulcer prevention, labor induction, or management of miscarriage/abortion). Studies examined the effect on specific biological markers related to the condition.

Phase I and II Data: Early-stage trials primarily focused on establishing the safety profile and determining the tolerable dosage range. Phase II studies also examined preliminary measures across various patient populations.
Key Phase III Findings: Phase III trials examined its performance in relation to existing treatments. These multi-center, randomized, controlled trials (RCTs) typically involved adult patients. Findings from a study of 500 patients indicated a decrease in disease activity over 12 months, with some research exploring a potential correlation with patient-reported measures.

Mechanistic Studies and Pharmacology

Research studied the compound's effect on specific biological pathways, which may involve mimicking the action of naturally occurring prostaglandins. These studies examined the compound's interaction with the target receptor.

Clinical Pharmacology: Clinical pharmacology studies provided data on the compound's stability and duration of presence in the body.

Evidence for Combination Use (Condition A)

Combination therapy was evaluated for severe cases. Trials assessed whether combining the investigational agent with a standard therapy could lead to better outcomes than either treatment alone.

Observed Results: The initial data reflected some differences in outcomes for patients receiving the combination, but the overall evidence remains limited and does not yet reflect clear distinctions across all measured outcomes.

Subgroup Tolerability

Studies included elderly patients to assess tolerability across different age groups. Separate studies explored the drug's potential impact on pain and fatigue. The medication was studied in patients with liver impairment to understand the possible effects on safety and dose findings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Misoclear (FAQ)

Q: Does Misoclear cause pain?

A: Yes, according to official product information, abdominal pain and cramping are common effects associated with the use of Misoclear. These effects occur as the treatment is working. The level of pain may vary from person to person.

Q: Can I eat or drink before taking Misoclear?

A: Regulatory documents indicate that Misoclear can be taken with or without food and drink. Official documents often advise against alcohol consumption around the time of treatment, stating that it may increase the risk of side effects.

Q: What happens if I vomit after taking Misoclear?

A: The official product information does not provide specific instructions for vomiting. However, the documentation suggests contacting a healthcare provider if vomiting occurs shortly after administration, as this may affect the efficacy of the dose.

Q: How long does Misoclear stay in my system?

A: Studies show that the active ingredient in Misoclear is rapidly absorbed and then quickly processed by the body. According to the regulatory summary, the medicine is eliminated from the body within a few hours.

Q: Will Misoclear affect my future fertility?

A: Official research and regulatory sources do not indicate that Misoclear has a negative impact on future fertility. Fertility generally returns shortly after the treatment is complete.

Q: Is it normal to have heavy bleeding after taking Misoclear?

A: Yes, heavy vaginal bleeding is a very common and expected effect of Misoclear as the body expels the pregnancy. This bleeding is usually heavier than a normal period. Official documents also mention that some people may experience spotting or lighter bleeding.

Q: Can I take ibuprofen or paracetamol for pain after Misoclear?

A: Official product information suggests that pain relievers may be used to manage the abdominal cramping associated with Misoclear. The official product information does not generally list specific interactions or warnings against using common over-the-counter pain relievers like ibuprofen or paracetamol for this pain.

Q: Can I use tampons or menstrual cups after taking Misoclear?

A: Regulatory guidance suggests avoiding the use of tampons, menstrual cups, and vaginal douches during the bleeding phase after taking Misoclear. Regulatory documents recommend using sanitary pads instead of internal products to help reduce the risk of infection.

Q: What is the likelihood of the treatment failing?

A: Studies and official information indicate that Misoclear is highly effective when used as directed, but no medication is 100% effective. A small percentage of treatments may fail, meaning the pregnancy continues. In the event of treatment failure, medical intervention may be required as part of the overall care plan.

Q: Will Misoclear affect my next menstrual period?

A: According to official product information, the menstrual period typically returns within 4 to 6 weeks after the treatment. The timing may vary slightly for different people.

Q: What are the very rare side effects of Misoclear?

A: Official documents list some side effects that are considered rare or very rare. These may include a severe allergic reaction or other serious complications, though these occur in a very small number of people. The full list of potential side effects is detailed in the patient information leaflet.

Q: Do I need to take antibiotics with Misoclear?

A: Regulatory documents do not state that antibiotics are a required part of the standard Misoclear treatment protocol. The official product documentation notes that a healthcare provider may decide to prescribe antibiotics in certain individual circumstances to prevent infection.

Q: What is Misoclear used for?

A: Misoclear is officially approved and indicated for the medical termination of an intrauterine pregnancy up to a certain gestational age. It works by causing the uterus to contract and expel the pregnancy.

How should Misoclear be stored and disposed of?

Storage and Disposal Requirements for Misoclear

Misoclear (Misoprostol Tablets) requires specific conditions to maintain its effectiveness, as documented in official regulatory labeling.

Official Storage Constraints

The tablets must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), with permitted temperature excursions. It is mandatory to keep the product from freezing and store it in a dry area, protected from light. Due to the product's sensitivity to moisture, it should be kept in its original container or packaging. For safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Misoclear must not be kept. Patients are instructed to ask a healthcare professional or local pharmacy for guidance on proper disposal, ensuring compliance with local environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Bangladesh

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z